详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Rezvilutamide (REZ) plus docetaxel (DOC) in patients (pts) with chemo-naive metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone (ABI)

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：

机构： [1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China [2]Clinical Trial Center and National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, China [3]Department of Urology Surgery, Hunan Cancer Hospital, Changsha, China [4]Uro-Oncology, Chongqing University Cancer Hospital, Chongqing, China [5]Urological Oncology, Sichuan Cancer Hospital, Chengdu, China [6]Department of Urology, Second Affiliated Hospital of Anhui Medical University, Hefei, China [7]Urinary Surgery, The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University, Chongqing, China [8]Department of Urology, Zhejiang Provincial People's Hospital, Hangzhou, China [9]Clinical Development-Oncology, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China [10]Clinical Statistics, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China [11]Clinical Pharmacology, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China

出处：

ISSN：

基金：

语种：

WOS：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2023]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

影响因子： 42.1 最新[2023版] 37.4 最新五年平均 42.1 出版当年[2023版] 0 出版当年五年平均 42.1 出版前一年[2023版]

第一作者：

第一作者机构： [1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China

推荐引用方式(GB/T 7714)：

APA：

MLA：